Drugs / HEC-151
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07376200 | Feb → Sep 2026 expected | — | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC-151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07376200 ↗ |
| Known as | HEC-151 Injection | “The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1.” NCT07376200 ↗ |
| Route | Subcutaneous | “The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1.” NCT07376200 ↗ |